Research Article
Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
Figure 3
Progression-free survival in relation to the status of EGFR gene activating mutations.